We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Arix Bioscience Plc | LSE:ARIX | London | Ordinary Share | GB00BD045071 | ORD 0.001P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 142.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Arix Bioscience PLC (ARIX) Arix Managing Director to Participate in Fireside Chat at the Jefferies Healthcare Conference 08-Nov-2021 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Arix Managing Director to Participate in Fireside Chat at the Jefferies Healthcare Conference
LONDON, 8 November 2021: Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that Mark Chin, Managing Director, is scheduled to participate in a virtual analyst-led fireside chat with Matthew Hose, Equity Research Analyst, at Jefferies London Healthcare Conference taking place in person and virtually from 16-19 November 2021 in London.
A webcast of the fireside chat will be available on the Jefferies conference portal and the replay will be available afterwards on the Investor Relations section of Arix's website here.
ENDS
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc +44 (0) 20 7290 1050 ir@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Manel Mateus +44 (0)20 8078 4357 optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
-----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071 Category Code: MSCM TIDM: ARIX LEI Code: 213800OVT3AHQCXNIX43 OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State Sequence No.: 126161 EQS News ID: 1246669 End of Announcement EQS News Service =------------------------------------------------------------------------------------
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1246669&application_name=news
(END) Dow Jones Newswires
November 08, 2021 02:00 ET (07:00 GMT)
1 Year Arix Bioscience Chart |
1 Month Arix Bioscience Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions